AusBiotech 2024 stand partners

AdvanCell

AdvanCell is an Australian clinical stage radiopharmaceutical company developing ²¹²Pb-based Targeted Alpha Therapies (TAT). AdvanCell’s proprietary alpha isotope generator technology allows for a scalable supply of ²¹²Pb for the clinical development and translation of the company’s therapeutic pipeline of novel TAT. AdvanCell’s lead asset ADVC001, a class leading ²¹²Pb-PSMA, is currently being evaluated in a Phase 1b/2a clinical trial in patients with metastatic castration-resistant prostate cancer at the Royal Brisbane and Women’s Hospital and Princess Alexandra Hospital in Brisbane, with expansion to additional sites in Australia and the US in planning.

AdvanCell’s new Brisbane-based, GMP-compliant radiopharmaceutical manufacturing facility marks a pivotal milestone in expanding the company’s manufacturing capabilities. This facility will  enable global scale CMC production and source manufacturing.

CAD-IT Australia

CAD-IT Australia specialises in delivering tailored digital solutions designed to address the unique challenges faced by the life science sector. CAD-IT solutions bring significant advantages by streamlining regulatory compliance and quality management, real-time monitoring in manufacturing and smooth data management in R&D.

Life Sciences is pivotal to CAD-IT Australia's vision, fueling innovation, healthcare strides, and eco-friendly solutions. CAT-IT’s dedication to Life Science technologies, showcased at events like the AusBiotech conference, demonstrates its commitment to this sector and how CAD-IT contributes to shaping the industry's future, fostering collaboration, and driving positive change.

Gelomics

Gelomics accelerates drug development by enabling pharmaceutical companies to grow human tissue models as an ethical, cost-effective, and highly predictive alternative to animal experiments. Addressing a US $50bn+ market opportunity, the company has achieved significant traction in 22 international markets, acquiring more than 300 return customers with >80% demo-to-sales conversion and >20% month-over-month revenue growth. Gelomics is actively seeking distributors, customers, investors, and strategic partners to support their strategic entry in the US market.

Sanofi Translational Science Hub

The Sanofi Translational Science Hub connects world-class researchers in Queensland with Sanofi scientists in France and the US, creating a first-of-its-kind, global scientific community focused on mRNA technology and translational science. The Translational Science Hub is proudly supported by Sanofi, Griffith University, The University of Queensland and the Queensland Government.

Main focus areas:

• Optimise mRNA platform technology: Includes improving mRNA as a vaccine technology that can be used for multiple vaccine candidates and for therapeutics.
• Bring together the local academic and industry network: By having a R&D presence in Australia, Sanofi is able to work more closely with the local scientific talent and help create a strong and sustainable scientific ecosystem.
• Advance the development of vaccine candidates: New vaccines for influenza, RSV, chlamydia and acne are being explored in Queensland.

Southern RNA

Southern RNA is Australia’s pioneering Contract Development and Manufacturing Organisation (CDMO) specialising in RNA-based therapeutics and vaccines. Southern RNA’s integrates the rapid design turnover of RNA-based drugs with its manufacturing platform and streamlined approval processes to accelerate the path from discovery to clinical trials.

Southern RNA has built a team of industry and RNA experts together with a robust pharmaceutical quality system to support a wide range of services, including custom RNA production, tech transfer, engineering run, and clinical-grade manufacturing, analytical assay development (design, qualification, validation), upstream and downstream process development, raw material manufacturing and supply (E. coli cell bank, pDNA, Cap analog).

Translational Research Institute

The Translational Research Institute (TRI) is a unique, Australian-first initiative of ‘bench to bedside’ medical research. TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.

The TRI facility gives early-phase start up biotech companies time to establish, build, test and develop their products and provides a supportive environment to advance medical discoveries to healthcare solutions. In response to the lack of scale-up manufacturing facilities in Australia, TRI has secured funding to build Translational Manufacturing at TRI (TM@TRI), Australia’s first scale-up biomedical manufacturing facility, supporting mid-stage biotech companies as they mature and manufacture products for Phase II and III studies.

Vaxxas Pty Ltd

Vaxxas is an Australian biotech company commercialising novel technology to enhance the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to helping the world rethink what's possible with vaccines.

Vaxxas' approach, which has been validated in human clinical studies, can enhance the efficiency and effectiveness of a vaccine's immune response. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain".

In June 2023, with support from the Queensland Government, Vaxxas opened its state-of-the-art biomedical facility in Brisbane. From this site, the company plans to manufacture its vaccine products for late-stage clinical trials and first commercial use.